key: cord-0288531-ht1e8gmn
authors: Hou, Y.; Zhou, Y.; Gack, M. U.; Luo, Y.; Jehi, L.; Chan, T.; Yu, H.; Eng, C.; Pieper, A. A.; Cheng, F.
title: Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients
date: 2021-09-16
journal: nan
DOI: 10.1101/2021.09.13.21263504
sha: 56af025e9addca2bb9764e7b0bc3ad947bfcae47
doc_id: 288531
cord_uid: ht1e8gmn

Coronavirus Disease 2019 (COVID-19) is especially severe in aged patients, defined as 65 years or older, for reasons that are currently unknown. To investigate the underlying basis for this vulnerability, we performed multimodal data analyses on immunity, inflammation, and COVID-19 incidence and severity as a function of age. Our analysis leveraged age-specific COVID-19 mortality and laboratory testing from a large COVID-19 registry, along with epidemiological data of ~3.4 million individuals, large-scale deep immune cell profiling data, and single-cell RNA-sequencing data from aged COVID-19 patients across diverse populations. We found that decreased lymphocyte count and elevated inflammatory markers (C-reactive protein, D-dimer, and neutrophil-lymphocyte ratio) are significantly associated with age-specific COVID-19 severities. We identified the reduced abundance of naive CD8 T cells with decreased expression of antiviral defense genes (i.e., IFITM3 and TRIM22) in aged severe COVID-19 patients. Older individuals with severe COVID-19 displayed type I & II interferons deficiencies, which is correlated with SARS-CoV-2 viral load. Elevated expression of SARS-CoV-2 entry factors and reduced expression of antiviral defense genes (LY6E and IFNAR1) in the secretory cells are associated with critical COVID-19 in aged individuals. Mechanistically, we identified strong TGF-beta mediated immune-epithelial cell interactions (i.e., secretory-T regulatory cells) in aged individuals with critical COVID-19. Taken together, our findings point to immuno-inflammatory factors that could be targeted therapeutically to reduce morbidity and mortality in aged COVID-19 patients.

Coronavirus Disease 2019 (COVID- 19) , a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), has been diagnosed in more than 170 million people globally, with 3.5 million deaths since December 2019 (data on May 31, 2021) . Although a serious risk at any age, SARS-CoV-2 infection is particularly debilitating and deadly for aged patients, defined in this study as 65 years and older 1,2,3,4,5 . The molecular basis of this aging-related vulnerability is an important area of investigation as it is currently poorly understood. Impaired and dysregulated host immunity, including both innate and adaptive immunity, have been hypothesized as age-based factors in COVID-19 disease severity 4, 6 . Compared to younger individuals with COVID-19, aged individuals show disrupted antigen-specific adaptive immunity to SARS-CoV-2, such as reduced coordination of CD4-CD8 T cell responses 7 . In addition, aged individuals typically produce a less robust type I interferon (IFN) response to flu virus infections 8 , indicating compromised cellular antiviral defense in innate immunity. Indeed, 13% of aged patients with life-threatening COVID-19 display inborn errors in autoantibodies against type I IFN immunity 9 . In addition, aberrant immunosenescence and inflammation also play crucial roles in age-medicated COVID-19 morbidity and mortality 10 . For example, senescent cells become hyper-inflammatory in response to pathogen-associated molecular patterns, and senolytics reduce COVID-19-mortality in aged mice 11 . Based on these findings, we sought to systematically identify whether there are specific immunoinflammatory determinants that promote age-associated COVID-19 severity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ;  https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint

To begin, we investigated the prevalence of COVID-19 disease among different age groups with nine months data collection. Analysis of U.S. Centers for Disease Control (CDC) epidemiological data from March to December, 2020 (Supplementary Tables 1-3 ) revealed that 80.5% of fatal-cases occurred in aged patients. Strikingly, this rate was 4.1 times higher than in 18-64 years old (19.5%), and 1,653 times higher than in 0-17 years old (0.05%, Fig. 1a) . Fatality prevalence was influenced by sex in both older and younger groups (Fig. 1b) . Notably, the relative fatality prevalence trend across these same three age groups from 2010-2020 with influenza virus was similar, (Fig. 1a) ,

indicating that age is a universal risk factor for viral infections, especially for older males.

Next, we used odds ratio (OR) adjusted for confounding factors to further evaluate the association between aging and four types of COVID-19 outcomes: hospitalization, intensive care unit (ICU) admission, and death. Specifically, we analyzed sex-and race- Fig. 1c) .

To further account for disease comorbidities, we next computed OR across different age groups using a large COVID-19 registry database with 12,651 aged (³ 65 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021 (Fig. 1c) , and death (OR = 40.35, 95% CI 19.80 -82.24). Subsequent Kaplan-Meier analysis further revealed an elevated cumulative hazard for hospitalization (p < 0.0001, Log-rank test, Supplementary Fig   1a) , including longer duration of hospitalization (average duration = 8.9 days; p = 1.4 Supplementary Fig 1b) , in COVID-19 patients. Taken together, our findings confirm an elevated likelihood of severe outcomes in aged COVID-19 patients have compared to younger patients, even when adjusted for all possible confounding factors.

As severe COVID-19 patients have been reported to have lower lymphocyte count 14 and higher C-reactive protein (CRP) 15 , we examined the Cleveland Clinic COVID-19 registry for differences in inflammatory biomarkers as a function of aging. Here, we found lower peripheral lymphocytes (adjusted p value [q] < 2.0 ´ 10 -16 , Mann-Whitney U test with Benjamini-Hochberg multiple test correction, Fig. 1d ) and higher circulating neutrophils in hospitalized aged COVID-19 patients (q =0.004, Fig. 1d ), compared to younger patients. We also found that the neutrophil-lymphocyte ratio (NLR), a marker of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 16 , was elevated in aged COVID-19 patients (q < 2.0 ´ 10 -16 , Fig.   1d ). In addition, the inflammatory markers D-dimer (q < 2.0 ´ 10 -16 , Fig 1e) and Creactive peptide (CRP) (q = 2.7 ´ 10 -10 , Fig 1e) were also significantly increased in hospitalized aged compared to hospitalized young COVID-19 patients. Taken together, our findings identify elevated inflammatory response and decreased lymphocyte count as potential mediators of severe COVID-19 outcomes in aged patients.

We next examined peripheral immune profiles 17 of hospitalized aged and younger COVID-19 patients by querying a dataset of 12 major immune cell types (% peripheral blood mononuclear cells [PBMCs] ) and 32 T cell subtypes (% CD3, Supplementary between aged and young hospitalized COVID-19 patients, including those in the ICU (Fig. 2a, c and Supplementary Fig. 2a) . However, both young and aged COVID-19 patients with ICU admission had a lower proportion of T cells (younger, q = 0.001; older, q=0.003) and pDC (younger, q = 0.009; older, q=0.004) (Fig. 2a, c) , as well as an elevated proportion of non-classic Monocytes (ncMono) (younger, q = 0.003; older, q=0.014, Fig. 2c ), compared to non-ICU patients. Further analysis of deep phenotyping T cell data revealed significantly fewer naïve CD8 T cells in hospitalized aged COVID-19 patients (q = 1.7 x 10 -11 , Fig. 2b, d) . Naïve CD8 T cell-mediated homeostasis is an important component of antiviral defense 18 , and the naïve CD8 T cell receptor repertoire . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint negatively correlated with age in COVID-19 patients 19 . Reduced abundance of naïve CD8 T cells could dysregulate CD8 T cell pool homeostasis and perturb immunity.

Next, we compared the plasma profile of 71 cytokines and chemokines 17 between hospitalized aged and younger COVID-19 patients (Supplementary Table 5 ).

Historically, increased IL-6, IL-8, IL-10 and IL-27 levels have been associated with severe COVID-19 20, 21 . Here, we found elevated IL-8 (also named CXCL8) and IL-27 expression in aged COVID-19 patients (q = 0.013, Fig. 2g and Supplementary Fig.   2b ). As IL-8 is a pro-inflammatory cytokine that recruits and activates neutrophils 22 , its elevation is consistent with our previously noted elevated neutrophil count and NLR in hospitalized aged COVID-19 patients (Fig. 1d) . Furthermore, younger, but not aged, COVID-19 ICU patients also showed elevated IL-10 ( Supplementary Fig. 2) , a key feature of cytokine storm 23, 24 . In addition, elevated IL-6 was observed in both younger (q = 0.020) and aged ICU patients, (q=0.002), compared to non-ICU patients (Fig. 2g) . 

Because we observed loss of CD8 naïve T cells and T effector memory cells in hospitalized aged COVID-19 patients (Fig2 b, d) , we examined a single-cell transcriptomic dataset of CD8 T cells 25 in order to search for aging-related molecular . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint mechanisms in a cell type-specific manner. Uniform Manifold Approximation and Projection 26 (UMAP) revealed 5 distinct CD8 sub-clusters (Fig. 3a, b) , including naïve CD8, T central memory (Tcm), Tem, CD8-proliferation, and CD8 T effector. Comparing to severe young COVID-19 patients, up-regulated genes (q < 0.05, log fold change > 0.1) in CD8 naïve T cells from aged patients formed a network module (the largest connected component) in the human protein-protein interactome (Fig. 3c) . This agespecific network module was significantly enriched in several pathways, including apoptosis (q = 0.013), human T cell leukemia virus 1 infection (q = 0.013), and TNF signaling (q = 0.014, Fig. 3c ). In particular, the apoptosis gene cathepsin D 27 (CTSD) was highly expressed in naïve CD8 T cells from aged severe COVID-19 patients (q < 2.0 x 10 -16 ). Down-regulated genes, such as interferon-stimulated genes IFITM3 and TRIM22, in CD8 naïve T cells from aged COVID-19 patients were enriched in type I & II IFN signaling pathways (Fig. 3c) . In addition, the transcription factor STAT1, an important downstream factor in type I & II IFN signaling pathways 28 , was downregulated in CD8 naïve T cells in aged COVID-19 patients (Fig. 3c) . Notably, the SARS-CoV-1 NSP1 protein impedes type I & II IFN signaling 29 by attenuating STAT1 phosphorylation 30 . Thus, IFN deficiencies in CD8 naïve T cells may contribute to increased severity of COVID-19 disease in aged patients.

To further investigate the relationship between viral load and COVID-19 disease severity, we analyzed bulk RNA-seq data from nasopharyngeal samples 31 (see Methods). Consistent with our findings in naïve CD8 T cells, expression levels of IFNα . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint genes (IFNA1, IFNA5, IFNA7 and IFNA8) were significantly decreased in aged patients with high viral load (Fig. 4a) . In addition, expression of IFNG was decreased in aged patients with low viral load (Supplementary Fig. 4) . Notably, we found that the IFNstimulated antiviral genes, 32 including IFIT1 and OAS1 (2'-5'-Oligoadenylate Synthetase 1), were down-regulated in aged patients with a higher viral load (Fig. 4b) 

We next investigated age-and cell type-specific expression of SARS-CoV-2 entry factors using a single-cell RNA-sequencing dataset 36 (scRNA-seq, see Methods) from . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. nasal tissue of critical (n = 11) and moderate COVID-19 patients (n = 8, see Methods).

In total, the scRNA-seq dataset contained 115,895 cells across 15 well-annotated cell types within two main cell populations: epithelial cells (6 cell types) and immune cells (9 cell types).

We found that secretory and ciliated cells in aged COVID-19 patients display reduced abundance of angiotensin converting enzyme-2 (ACE2), a key SARS-CoV-2 docking receptor 37 (Fig 4d) . However, the more recently identified SARS-CoV-2 docking receptor basigin 38 (BSG or CD147) was expressed in 95% of secretory cells in aged patients with critical COVID-19 (Fig 4d, and Supplementary Table 6 ), most notably in Treg (regulatory T cell) and CLT (cytotoxic T) cells (Fig. 4d) . We also found that the S protein priming proteases TMPRSS2 39 and FURIN 24 were highly expressed in epithelial cells in critical and moderate COVID-19, with no differences between aged and young patients (Fig 4d, Supplementary Table 6 ). However, FURIN levels were increased in several immune cell types, including Treg and CLT, in aged patients with critical COVID19 (Fig 4d) . Taken together, our results suggest that elevated expression of two SARS-CoV-2 factors (BSG and FURIN) in Treg and CLT cells may contribute to the increased susceptibility of aged patients to COVID-19.

To further investigate the immunological mechanisms underlying age-associated COVID-19 outcomes, we performed GSEA to explore transcriptomic signatures on 22

immune pathways across 15 cell types derived from nasal tissue (see Methods). Here, we observed distinct immune responses between older and younger individuals with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Fig. 6 ) in epithelial and immune cell types. We next used CellphoneDB 40 to quantify ligand-receptor interactions between epithelial and immune cells and found an elevated number of significant ligand-receptor interactions involved in immune-epithelial interactions (p < 0.05, permutation test,

in aged patients with critical COVID-19 (Fig. 5a) . In addition, we also found a stronger immune-epithelial cell interaction network in aged patients. In particular, we noted that secretory-T regulatory cells (Treg) and non-resident macrophages (nrMa) displayed the highest connection with other cell types in aged patients with critical COVID-19 (Fig. 5a) .

We next analyzed ligand-receptor interactions of secretory/ciliated -immune cells in aged and younger patients with critical COVID-19 (Fig. 5b) , and identified higher levels in aged patients (p < 0.05, permutation test). For example, we found elevated expression of TGF-β genes (TGFB1, TGFB2 and TGFB3) and their interacting partners (Supplementary Fig. 1b) .

We also observed distinct immune-epithelial cell interactions in younger COVID-19 patients. For example, secretory and CTL cells expressed high levels of several ligand-receptor pairs, including HLA-B -KIR3DL2, TNF -RIPK1 and TNF -PTPRS (p < 0.05, permutation test), and secretory and Neu cells highly co-expressed CXCL2/3 and CXCR2 (p < 0.05, permutation test). In addition, we found that secretory/ciliated -. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint CTL cells showed a similar IFNG -IFNGR pattern, while the expression level in aged patients was much lower (Fig. 5b) . In particular, secretory/ciliated -CTL cell interaction in younger patients showed strong IFNG -IFNGR interaction compared to aged patients with moderate COVID-19 (Supplementary Fig. 6 ). In summary, these observations revealed that immune-epithelial cell interactions are associated with critical COVID-19 in aged patients. In particular, reduced expression of IFNR signaling is associated with greater severity of COVID-19 in aged individuals (Fig. 4a ).

This study provides a comprehensive analysis of immune profiles in aged and younger COVID-19 patients. Previous epidemiologic studies have identified age as an important risk factor for severe COVID-19 1,42,43 , and our large COVID-19 registry data further confirmed the elevated likelihood of severe COVID-19 in aged individuals even after adjusting for sex, race, smoking and multiple disease comorbidities (Fig. 1c) .

Mechanistically, aged hospitalized COVID-19 patients showed elevated levels of Ddimer, CRP (Fig 1d) and NLR (Fig 1e) , which are inflammatory markers associated with severity and death in COVID-19 16, 44 .

Via deep immune cell profiling data analysis, we identified distinct immune responses in younger and aged COVID-19 patients (Fig. 6) . For example, both younger and aged COVID-19 patients showed increased ncMono cells and elevated IL6 (Fig. 2,   Fig. 6 ), while only aged COVID-19 patients displayed elevated plasma IL8 and IL27 ( Fig. 2g and Supplementary Fig. 2b) . IL-6 is a potential therapeutic target since it is a . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint critical mediator of cytokine storm in COVID-19 45 . However, a recent Phase III clinical trial (NCT04320615) showed no reduced mortality in severe COVID-19 patients treated with the anti-IL-6R monoclonal antibody tocilizumab 46 . Younger COVID-19 patients in the ICU also showed significantly higher IL10 (Supplementary Fig. 2b) . Our observations suggest that targeting IL-10 might reduce mortality in younger patients with severe COVID-19, whereas IL-8-and IL-27-based therapies might benefit aged COVID-19 patients.

We also found reduced lymphocytes in hospitalized aged COVID-19 patients (Fig.   1d ). In particular, the abundance of naïve CD8 T cells was decreased in aged patients with severe COVID-19 (Fig. 2d) . Reduction of naïve CD8 T cell is a hallmark of immunosenescence in older individuals 47 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint expression of type I IFN genes (Fig. 3c, 4a, 5b) . Notably, aged patients with high SARS-CoV-2 viral load show reduced expression of OAS1 and IFNA1, IFNA5, and IFNA7 (Fig. 4a) compared to younger patients. On the contrary, aged patients with high SARS-CoV-2 viral load have elevated expression of the pro-inflammatory cytokine IL-8 and decreased lymphocyte cell counts in plasma (Fig. 4c) , demonstrating dysregulation of cytokine responses that has been well described for COVID-19 52 . Of note, the dysregulated cytokine response is likely the effect of a variety of immunomodulatory strategies employed by SARS-CoV-2 that are used to manipulate specific signaling pathways that lead to cytokine induction such as the RIG-I-like receptor pathway.

Therefore, the type I IFN pathway offers a potential therapeutic target for aged severe COVID-19 patients.

Although aged adults show increased susceptibility to SARS-CoV-2 infection compared to children 5 , we did not find differences in SARS-CoV-2 viral load in the upper airways between younger and aged patients (Supplementary Fig. 7) . Using large-scale scRNA-seq data analysis, we did find, however, that the SARS-CoV-2 entry genes (ACE2, BSG, TMPRSS2, FURIN and NPR1) showed cell type-specific expression profiles in both aged and younger individuals. In aged patients with critical COVID-19, expression of BSG was increased in secretory, rMa and CTL cells, and elevated expression of FURIN was found in Treg and CTL cells. Thus, cell type-specific host factor expression may play an important role in age-mediated disease susceptibility and severity in COVID-19.

We also identified age-specific increases in immune-epithelial cell interactions. For example, we found strong TGF-β mediated immune-epithelial cell interactions in aged . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint severe COVID-19 patients. TGF-β plays a crucial role in pulmonary fibrosis 53, 54 , which is a common complication in severe COVID-19 patients 55 . The nucleocapsid protein of SARS-CoV-1 also upregulates TGF-β expression 56 Lastly, we acknowledge the potential limitations of our study. Although we inspected omics data from multiple tissues, including PBMCs, plasma, and nasal tissues, additional analysis of other COVID-19 and aging relevant tissues, such as lung and brain, should be investigated in the future. In addition, our COVID-19 database and omics data were generated from acute COVID-19 patients, and identification of the underlying genetic and molecular basis of aging differences for long-haul COVID-19 patients will be an important area of future investigation 60 . Finally, investigation of COVID-19 vaccine responses between aged and young patients are also warranted in the future.

'Young' was defined as 18 to 55 years of age, and 'aged' was defined as ³ 65 years old.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We collated U.S. COVID-19 Case Surveillance Public Use Data from the CDC website (https://healthdata.gov/dataset/covid-19-case-surveillance-public-use-data) from December, 2019 to December 28 th , 2020. This dataset includes age-stratified COVID-19 case counts in hospitalization, ICU admission, death, sex, and race. We extracted two age subgroups from all laboratory-confirmed cases using the following criteria: i) the age range of younger group from 20 to 49 years, and the age range of older group over than 60 years (Supplementary Table 2) ; ii) deletion of all cases in which sex and race information was missing. In total, the younger subgroup includes 2,369,919 cases, with 94,161 in hospitalization, 9,138 in ICU admission, and 6,469 death cases. The older subgroup has 1,048,011 cases in total, with 243,109 in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint hospitalization, 29,671 in ICU admission, and 124,566 death cases. This dataset was used to determine odds ratio analysis.

We used institutional review board-approved COVID-19 registry data, including 45 Table 3) .

We conducted a series of retrospective studies to test the association of aging with COVID-19 outcomes, including hospitalization, ICU admission, mechanical ventilation, and death. Data were extracted from electronic health records (EPIC Systems), and patient data was managed using REDCap electronic data capture tools. To ensure data quality, a study team trained on uniform sources for the study variables manually checked all datasets. Statistical analysis for smoking, hypertension, diabetes, coronary . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

The odds ratio (OR) was used to measure the association between COVID-19 outcomes and aging based on logistic regression. An OR > 1 indicates that aged patients are associated with a higher likelihood of the outcome. To reduce the bias from confounding factors, we employed OR analysis in two datasets. For U.S. CDC datasets, the OR model was adjusted by sex and race, due to limited information of other confounding factors. However, in the COVID-19 registry we adjusted for sex, race, smoking, hypertension, diabetes, coronary artery disease, asthma, emphysema, and chronic obstructive pulmonary disease. The Kaplan-Meier method was used to estimate the cumulative hazard of hospitalization of COVID-19 patients across age groups. For hospitalization outcome, the time was calculated from the start date of COVID-19 symptoms to hospital admission date. Log-rank test was used for comparison across different age groups with Benjamini & Hochberg adjustment. Cumulative hazard analysis was performed using the Survival and Survminer packages in R 3.6.0 (https://www.r-project.org). Supplementary Table 4 .

Two single-cell sequencing datasets. In this study, we used two COVID-19 singlecell datasets (Supplementary Table 1) . First, the CD8 + T cells dataset 25 is a sub-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint dataset from original PBMC single cell data 61 . We re-analyzed 59,815 single cell transcriptomes of CD8 T cells, which revealed 5 distinct CD8 sub-clusters (Fig. 3a) , including CD8 naïve (CCR7 + , LEF1 + ), Tcm (GZMK + ,LTB + , CCR7 -), Tem (GZMK + , CCR7 -), CD8-proliferation (MKI67 + ), CD8 T effector (ZNF683 + , GZMB + , GNLY + ). Based on our aging criteria, the final subpopulation included 32 aged patients (mild/moderate, n = 20; critical/severe, n = 12) and 40 younger patients (mild/moderate, n = 27; critical/severe, n = 13). Second, a single cell dataset from nasal tissues 36 Bulk RNA-sequencing dataset in nasal tissue 31 . The dataset was publically available from NCBI GEO database (GSE152075). Based on original meta-information, we extracted COVID-19 positive sample data with high or low viral load, deleting samples in which sex and age information were missing. 147 bulk RNA-seq samples were used in this study, including 61 aged patients (high viral load n = 27, low viral load n =34) and 86 younger patients (high viral load n = 46, low viral load n =40).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

All single-cell data analyses and visualizations were performed with the R package Seurat v3.1. 4 40 . The data quality filtering was strictly followed by the original . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint literature 19, 36 . "NormalizeData" was used to normalize the data. 

All bulk RNA-sequencing data analysis started from raw counts value. R package edgeR 63 v3.12 was used to analyze differentially expressed genes in older vs. younger groups. Correction for sex and batch effects was added into the formula of design model. Statistical significance p values were adjusted by Benjamini-Hochberg (q value) method. Differentially expressed genes were identified as adjusted p value (q) < 0.05 and log fold change > 0.5.

To evaluated the immune pathway profiles in young and aged COVID-19 patients, GSEA was conducted as previously described 64 . Immune gene profiles were retrieved . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263504 doi: medRxiv preprint from the KEGG database 65 . We selected 22 immune-related pathways and 1241 genes from KEGG belonging to the immune system subtype. For each cell type, we performed a GSEA on the list of differential expressed genes (DEGs) ranked by the log2FC. The normalized enrichment score (NES, Equation 1) was calculated for 22 immune pathways in young and aged specific gene sets (Supplementary Fig 2a) , 

Statistical tests for assessing categorical data through χ2 test, and the two-tailed Mann-Whitney U test was used to compare the difference of continuous variable by aged vs.

younger. Spearman's ρ was assessed for correlation between two variables. Statistical significance level was set at p < 0.05 and corrected by Benjamini-Hochberg (false discovery rate) method. All statistical analysis was performed by SciPy Statistics (https://docs.scipy.org/doc/scipy/reference/stats.html#module-scipy.stats).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors declare that they have no competing interests. 

The clinical and transcriptomic datasets used in this study are public available, the details see Supplementary Table 1 . The code for single cell analysis can be found in https://github.com/ChengF-Lab/COVID-19_Map.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Analysis of SARS-CoV-2 viral load and related entry gene expression in nasal tissues. a, Volcano plot showing the differential genes of bulk RNA-sequencing data in aged versus younger patients in high viral load nasal tissues. b, Gene-set enrichment analysis (GSEA) of 22 immune pathways for differential gene set in two comparable conditions. The gradient color bar shows the NES score (see Method). NES score > 0 and q < 0.05 indicates that up-regulated DEGs in aged vs. young are significantly enriched in immune pathways, while NES score < 0 and q < 0.05 indicates down-regulated DEGs in aged vs. young are significantly enriched in immune pathways. Black dots denote FDR < 0.05. c, Boxplot showing the lab testing data changes in aged and younger COVID-19 patients with high (> 4.5 log10 RNA copies/ml) and low (< 4.5 log10 RNA copies/ml) viral load. d, SARS-CoV-2 related entry gene expression profile across 15 cell types of nasal tissue between aged and younger patients. The size of dot denotes the percentage of the positive cell which expressed the tested genes. The gradient color bar represents the z-score scaled average expression of genes in each cell type. 

Age-specific mortality and immunity patterns of SARS-CoV-2

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses

Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity

Age-dependent effects in the transmission and control of COVID-19 epidemics

Immune determinants of COVID-19 disease presentation and severity

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes

Autoantibodies against type I IFNs in patients with lifethreatening COVID-19

SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime

Senolytics reduce coronavirus-related mortality in old mice

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

COVID-19: immunopathogenesis and Immunotherapeutics

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

The Neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19

Sex differences in immune responses that underlie COVID-19 disease outcomes

Transcriptional control of effector and memory CD8+ T cell differentiation

COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

An inflammatory cytokine signature predicts COVID-19 severity and survival

A Potential Role of Interleukin 10 in COVID-19 Pathogenesis

The role of interleukin-8 in inflammation and mechanisms of regulation

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Single-cell multi-omics analysis of the immune response in COVID-19

Dimensionality reduction for visualizing single-cell data using UMAP

Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury

Cross-regulation of signaling pathways by interferongamma: implications for immune responses and autoimmune diseases

An aberrant STAT pathway is central to COVID-19

Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain

In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age

Interferon-inducible antiviral effectors

Type I interferon production induced by RIG-I-like receptors

ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity

Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes

SARS-CoV-2 in severe COVID-19 induces a TGF-βdominated chronic immune response that does not target itself

Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada

Factors associated with COVID-19-related death using OpenSAFELY

Associations of procalcitonin, C-reaction protein and neutrophil-tolymphocyte ratio with mortality in hospitalized COVID-19 patients in China

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Naive T cell maintenance and function in human aging

Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity

Type I interferons in infectious disease

Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19

A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity

Dysregulation of type I interferon responses in COVID-19

Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)

Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis

Can biomarkers of extracellular matrix remodelling and wound healing be used to identify high risk patients infected with SARS-CoV-2?: lessons learned from pulmonary fibrosis

Severe acute respiratory syndromeassociated coronavirus nucleocapsid protein interacts with Smad3 and . CC-BY-NC-ND 4growth factor-beta signaling

Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target

Primidone blocks RIPK1-driven cell death and inflammation

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

Attributes and predictors of long COVID

Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells

SARS-CoV-2 viral load is associated with increased disease severity and mortality

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

KEGG: new perspectives on genomes, pathways, diseases and drugs

Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study

Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture

Comparison of the abundance of B cells in PBMCs and cytokines in plasma between aged and younger COVID-19 patients. a, The abundance of B cells subtype in all CD3 positive cells. b, Boxplot showing the plasma levels of cytokines and chemokines between younger and aged COVID-19 patients

Funding: This work was supported by the National Institute of Aging (R01AG066707 and 3R01AG066707-01S1) and the National Heart, Lung, and Blood Institute (R00HL138272) to F.C. This work has also been supported by the National Institute of Neurological Disorders and Stroke (3R01NS097719-04S1) to F.C. and L.J. This work